The MAPI Group has developed unique expertise in Phase IIIb and IV clinical trials. These aim to introduce a product about to be licensed for marketing or with a recent license (AMM), and to provide detailed knowledge of its use on a wide scale.
In France, the time gap between granting of the AMM and commercialization presents the pharmaceutical industry with a unique opportunity to train future prescribers on how to handle the product.
Such studies need to be carried out according to clinical trial standards, adapted (in particular for phase IV) to take into account medical marketing factors. Creativity and experience are required to set up protocols that will attract and secure the support of doctors, the future prescribers of the product.
The PATIENTs’ involvement in these protocols is particularly relevant, as it gives them prior experience of a new drug. The protocols often contain measurement of patient-related criteria (Satisfaction, Quality of Life...) and the MAPI Group’s combined expertise, focusing on the patient, pays off fully in this area.
Our ability to bring into play and coordinate large teams (in particular CRAs) for limited periods is yet another plus factor in management of this type of study.
Visit the site of the Mapi Group Company that specializes in this service.
Version française 